In a wide-ranging interview with USA TODAY, Melinda Gates talks about the goal of her new donation, global health, education and finding hope.
Author: Karen Weintraub, USA TODAY
‘Very inconsistent’: 2 allergic reactions in the UK to COVID-19 vaccine puzzle researchers
British regulators advised people with severe allergies not to take Pfizer vaccine. One US researcher says that would be a ‘showstopper’ here.
‘No surprises’: 53-page FDA report reinforces safety and effectiveness of Pfizer’s COVID-19 vaccine candidate
FDA summary on Pfizer’s candidate COVID-19 vaccine supports earlier findings that it is safe and will prevent 95% of people from becoming sick.
Continuing COVID-19 vaccine trials may put some volunteers at unnecessary risk. Is that ethical?
The success of candidate vaccines by Pfizer/BioNTech and Moderna raises ethical questions about continuing placebo trials in which some may get sick.
Deliver a safe, effective COVID-19 vaccine in less than a year? Impossible. Meet Moncef Slaoui.
As science adviser of Operation Warp Speed, the veteran pharmaceutical executive helped usher a coronavirus vaccine to the US market in record time.
Moderna becomes second company to request emergency FDA authorization for COVID-19 vaccine candidate
Moderna will be the second coronavirus vaccine maker to request authorization from the government after similarly positive trial results for Pfizer.
Pfizer and Moderna use mRNA in their COVID-19 vaccines. This never-before-used technology could transform how science fights diseases.
Though messenger RNA technology like Pfizer, Moderna use hasn’t grabbed headlines before now, some researchers have been working on it for decades.
Infected again or endless COVID? How the ‘reinfection phenomenon’ could impact vaccines, herd immunity and human behavior.
Can you get it again? Scientists are still investigating to find out how long the immune system can keep someone safe from COVID-19 after infection.
Pfizer’s COVID-19 vaccine candidate shown to be 90% effective in early findings
Pfizer is the first drug company to release data from a large, Phase 3 trial, designed to show both effectiveness and safety.
Pfizer has expanded its COVID-19 vaccine trial to include teens. Some say it’s risky. Others argue it’s necessary.
After months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16.